Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), Vir Biotechnology (VIR)
at www.tipranks.com (Mon, 19-Oct 8:20 AM)
Vir Biotechnology’s Gilead deal puts $90 million upfront on the PRO-XTEN dual-masked T-cell engager platform
Market Chameleon (Wed, 14-Oct 8:56 AM)
Vir Biotechnology highlights VIR-5500 Fast Track status as Phase 3 planning targets 2027 in prostate cancer
Market Chameleon (Fri, 9-Oct 11:54 AM)
Vir Biotechnology says FDA Fast Track for VIR-5500 sets up a 2027 Phase 3 push in late-line prostate cancer
Market Chameleon (Thu, 8-Oct 9:34 AM)
